PWMG
CPRX

Private Wealth Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Private Wealth Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54K Buy
62
+6
+11% +$143 ﹤0.01% 1158
2025
Q4 		$1.31K Sell
56
-3
-5% -$67 ﹤0.01% 1198
2025
Q3 		$1.16K Sell
59
-21
-26% -$432 ﹤0.01% 1247
2025
Q2 		$1.74K Buy
80
+31
+63% +$732 ﹤0.01% 1126
2025
Q1 		$1.19K Sell
49
-4
-8% -$90 ﹤0.01% 1214
2024
Q4 		$1.11K Buy
+53
New +$1.14K ﹤0.01% 1270

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Private Wealth Management Group's CPRX Position: Q1 2026 in Review

Private Wealth Management Group increased its Catalyst Pharmaceutical (CPRX) stake by 11% in Q1 2026, buying an estimated $143 and bringing the position to 62 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Private Wealth Management Group first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.74K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Private Wealth Management Group held 62 shares of Catalyst Pharmaceutical worth $1.54K as of Q1 2026.
  • Private Wealth Management Group bought 6 Catalyst Pharmaceutical shares in Q1 2026, an estimated $143.
  • Catalyst Pharmaceutical made up ﹤0.01% of Private Wealth Management Group's portfolio in Q1 2026, its #1158 holding.
  • Private Wealth Management Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • Private Wealth Management Group's Catalyst Pharmaceutical position peaked at $1.74K in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Private Wealth Management Group's 13F filing for Q1 2026, filed 23 Apr 2026.